COG AEWS1031: A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma

Print this page

COG AEWS1031: A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma

To test the effect of a combination of vincristine, cyclophosphamide and topotecan added to the standard 5-drug chemotherapy interval compressed backbone on event-free and overall survival in children and young adults with Ewing Sarcoma.

Protocol Number111011
Principal InvestigatorRichard Drachtman
PhasePhase III
ScopeNational
Applicable Disease SitesBones and Joints
Participating InstitutionsRutgers Cancer Institute of New Jersey
Robert Wood Johnson Medical School
Robert Wood Johnson University Hospital in New Brunswick

For further information on this clinical trial, please contact us at 732-235-8675 or cinjclinicaltrials@umdnj.edu.